<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Envveno Medical Corp — News on 6ix</title>
<link>https://6ix.com/company/envveno-medical-corp</link>
<description>Latest news and press releases for Envveno Medical Corp on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 27 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/envveno-medical-corp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a44078dffbe2df10a935.webp</url>
<title>Envveno Medical Corp</title>
<link>https://6ix.com/company/envveno-medical-corp</link>
</image>
<item>
<title>enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System</title>
<link>https://6ix.com/company/envveno-medical-corp/news/envveno-medical-reports-full-year-2025-financial-results-and-highlights-strategic-advancement-of-envver-system</link>
<guid isPermaLink="true">https://6ix.com/company/envveno-medical-corp/news/envveno-medical-reports-full-year-2025-financial-results-and-highlights-strategic-advancement-of-envver-system</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>Company accelerated development of the enVVe® System, completing pre-clinical studies and progressing toward a 2026 pivotal trial initiationStrong financial</description>
</item>
<item>
<title>NorthStrive Fund II LP Calls on enVVeno Medical to Halt Clinical Spending Plans and Call Special Shareholder Meeting to Vote on Strategic Alternatives</title>
<link>https://6ix.com/company/envveno-medical-corp/news/northstrive-fund-ii-lp-calls-on-envveno-medical-to-halt-clinical-spending-plans-and-call-special-shareholder-meeting-to-vote-on-strategic-alternatives</link>
<guid isPermaLink="true">https://6ix.com/company/envveno-medical-corp/news/northstrive-fund-ii-lp-calls-on-envveno-medical-to-halt-clinical-spending-plans-and-call-special-shareholder-meeting-to-vote-on-strategic-alternatives</guid>
<pubDate>Tue, 03 Mar 2026 19:40:00 GMT</pubDate>
<description>NEWPORT BEACH, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- NorthStrive Fund II LP (“NorthStrive Fund II”), a subsidiary of NorthStrive Companies Inc., headquartered in Newport Beach, California, and beneficial owner of approximately 5.05% of the outstanding common stock of enVVeno Medical Corporation (“enVVeno” or the “Company”), today issued the following open letter to the Company’s Board of Directors (the “Board”) and fellow shareholders: Following NorthStrive Fund II’s Schedule 13D filing on</description>
</item>
<item>
<title>enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement</title>
<link>https://6ix.com/company/envveno-medical-corp/news/envveno-medical-regains-compliance-nasdaq-133000253</link>
<guid isPermaLink="true">https://6ix.com/company/envveno-medical-corp/news/envveno-medical-regains-compliance-nasdaq-133000253</guid>
<pubDate>Wed, 04 Feb 2026 13:30:00 GMT</pubDate>
<description>Company achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter is closed Reports Cash and Investments of approximately $28 million as of the Year Ended December 31, 2025 IRVINE, CA / ACCESS Newswire / February ...</description>
</item>
<item>
<title>enVVeno Medical Announces Reverse Stock Split</title>
<link>https://6ix.com/company/envveno-medical-corp/news/envveno-medical-announces-reverse-stock-130000001</link>
<guid isPermaLink="true">https://6ix.com/company/envveno-medical-corp/news/envveno-medical-announces-reverse-stock-130000001</guid>
<pubDate>Thu, 15 Jan 2026 13:00:00 GMT</pubDate>
<description>IRVINE, CA / ACCESS Newswire / January 15, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock ...</description>
</item>
<item>
<title>enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment</title>
<link>https://6ix.com/company/envveno-medical-corp/news/envveno-medical-nasdaq-nvno-participate-134800564</link>
<guid isPermaLink="true">https://6ix.com/company/envveno-medical-corp/news/envveno-medical-nasdaq-nvno-participate-134800564</guid>
<pubDate>Wed, 26 Nov 2025 13:48:00 GMT</pubDate>
<description>Moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Wednesday, December 3rd at 4:00 PM ET IRVINE, CA / ACCESS Newswire / November 26, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), ...</description>
</item>
<item>
<title>enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve</title>
<link>https://6ix.com/company/envveno-medical-corp/news/envveno-receives-unfavorable-appeal-decision-220000434</link>
<guid isPermaLink="true">https://6ix.com/company/envveno-medical-corp/news/envveno-receives-unfavorable-appeal-decision-220000434</guid>
<pubDate>Thu, 13 Nov 2025 22:00:00 GMT</pubDate>
<description>IRVINE, CA / ACCESS Newswire / November 13, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it has received an unfavorable ...</description>
</item>
<item>
<title>enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/envveno-medical-corp/news/envveno-medical-reports-third-quarter-120500632</link>
<guid isPermaLink="true">https://6ix.com/company/envveno-medical-corp/news/envveno-medical-reports-third-quarter-120500632</guid>
<pubDate>Fri, 31 Oct 2025 13:05:00 GMT</pubDate>
<description>- Cash and investments are sufficient to fund current operations through Q2 2027, not including VenoValve commercialization and the enVVe IDE study - Cash burn of $4.2 million in Q3 remains in line with projected quarterly range - Ongoing engagement ...</description>
</item>
<item>
<title>enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment</title>
<link>https://6ix.com/company/envveno-medical-corp/news/envveno-medical-nasdaq-nvno-participates-124500560</link>
<guid isPermaLink="true">https://6ix.com/company/envveno-medical-corp/news/envveno-medical-nasdaq-nvno-participates-124500560</guid>
<pubDate>Fri, 26 Sep 2025 12:45:00 GMT</pubDate>
<description>Watch the "What This Means" video here IRVINE, CA / ACCESS Newswire / September 26, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today ...</description>
</item>
<item>
<title>enVVeno Medical Updates Regulatory Status of VenoValve(R)</title>
<link>https://6ix.com/company/envveno-medical-corp/news/envveno-medical-updates-regulatory-status-124500652</link>
<guid isPermaLink="true">https://6ix.com/company/envveno-medical-corp/news/envveno-medical-updates-regulatory-status-124500652</guid>
<pubDate>Mon, 15 Sep 2025 12:45:00 GMT</pubDate>
<description>IRVINE, CA / ACCESS Newswire / September 15, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it will file a request ...</description>
</item>
<item>
<title>enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)</title>
<link>https://6ix.com/company/envveno-medical-corp/news/envveno-receives-not-approvable-letter-110000637</link>
<guid isPermaLink="true">https://6ix.com/company/envveno-medical-corp/news/envveno-receives-not-approvable-letter-110000637</guid>
<pubDate>Wed, 20 Aug 2025 11:00:00 GMT</pubDate>
<description>IRVINE, CA / ACCESS Newswire / August 20, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it has received a not-approvable ...</description>
</item>
<item>
<title>enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech</title>
<link>https://6ix.com/company/envveno-medical-corp/news/envveno-medical-present-webull-financial-132100414</link>
<guid isPermaLink="true">https://6ix.com/company/envveno-medical-corp/news/envveno-medical-present-webull-financial-132100414</guid>
<pubDate>Fri, 15 Aug 2025 13:21:00 GMT</pubDate>
<description>- Live webcast on Thursday, August 21stat 2:00 PM ET IRVINE, CA / ACCESS Newswire / August 15, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous ...</description>
</item>
<item>
<title>Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency</title>
<link>https://6ix.com/company/envveno-medical-corp/news/health-economic-study-shows-envveno-123000507</link>
<guid isPermaLink="true">https://6ix.com/company/envveno-medical-corp/news/health-economic-study-shows-envveno-123000507</guid>
<pubDate>Wed, 06 Aug 2025 12:30:00 GMT</pubDate>
<description>Clinical data and cost-effectiveness analysis demonstrates the VenoValve would provide both better health outcomes and lower costs compared to current standard of care treatments The VenoValve could potentially save $5.9 billion annually in healthcare ...</description>
</item>
<item>
<title>enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company</title>
<link>https://6ix.com/company/envveno-medical-corp/news/envveno-medical-participates-virtual-investor-130500351</link>
<guid isPermaLink="true">https://6ix.com/company/envveno-medical-corp/news/envveno-medical-participates-virtual-investor-130500351</guid>
<pubDate>Mon, 04 Aug 2025 13:05:00 GMT</pubDate>
<description>- enVVeno is developing the VenoValve as a potential treatment option for the approximately 2.5 million patients in the U.S. suffering from severe deep Chronic Venous Insufficiency - FDA decision expected in 2H'2025 - Access the "What This Means" ...</description>
</item>
<item>
<title>enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/envveno-medical-corp/news/envveno-medical-reports-second-quarter-120000567</link>
<guid isPermaLink="true">https://6ix.com/company/envveno-medical-corp/news/envveno-medical-reports-second-quarter-120000567</guid>
<pubDate>Fri, 01 Aug 2025 12:00:00 GMT</pubDate>
<description>- Cash burn of $3.8 million in Q2 remains in line with projected quarterly range - Cash and investments are sufficient to fund operations through Q3'2026 at current cash burn rate - Commercial readiness activities underway for a phased launch of VenoValve® ...</description>
</item>
<item>
<title>enVVeno Medical Participates in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference</title>
<link>https://6ix.com/company/envveno-medical-corp/news/envveno-medical-participates-virtual-investor-124500693</link>
<guid isPermaLink="true">https://6ix.com/company/envveno-medical-corp/news/envveno-medical-participates-virtual-investor-124500693</guid>
<pubDate>Tue, 22 Jul 2025 12:45:00 GMT</pubDate>
<description>- Video webcast now available on-demand IRVINE, CA / ACCESS Newswire / July 22, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today ...</description>
</item>
<item>
<title>Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting</title>
<link>https://6ix.com/company/envveno-medical-corp/news/positive-interim-2-data-envveno-120500753</link>
<guid isPermaLink="true">https://6ix.com/company/envveno-medical-corp/news/positive-interim-2-data-envveno-120500753</guid>
<pubDate>Fri, 06 Jun 2025 12:05:00 GMT</pubDate>
<description>Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline 83% of subjects maintained a clinically meaningful benefit with a 3 ...</description>
</item>
<item>
<title>enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer</title>
<link>https://6ix.com/company/envveno-medical-corp/news/envveno-medical-appoints-jennifer-bright-120500828</link>
<guid isPermaLink="true">https://6ix.com/company/envveno-medical-corp/news/envveno-medical-appoints-jennifer-bright-120500828</guid>
<pubDate>Mon, 19 May 2025 12:05:00 GMT</pubDate>
<description>IRVINE, CA / ACCESS Newswire / May 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, announced the appointment of Jennifer Bright as ...</description>
</item>
<item>
<title>enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer </title>
<link>https://6ix.com/company/envveno-medical-corp/news/envveno-medical-appoints-jennifer-bright-as-chief-financial-officer</link>
<guid isPermaLink="true">https://6ix.com/company/envveno-medical-corp/news/envveno-medical-appoints-jennifer-bright-as-chief-financial-officer</guid>
<pubDate>Mon, 19 May 2025 04:00:00 GMT</pubDate>
<description>IRVINE, CA / ACCESS Newswire / May 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care</description>
</item>
<item>
<title>Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery</title>
<link>https://6ix.com/company/envveno-medical-corp/news/three-venovalve-r-first-human-124500763</link>
<guid isPermaLink="true">https://6ix.com/company/envveno-medical-corp/news/three-venovalve-r-first-human-124500763</guid>
<pubDate>Tue, 13 May 2025 12:45:00 GMT</pubDate>
<description>Promising results from the first-in-human study demonstrated that, at three-years post implantation, VenoValve remained safe and effective--achieving a high rate of patency, restoring deep venous competence and maintaining clinical benefits Company ...</description>
</item>
<item>
<title>enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24</title>
<link>https://6ix.com/company/envveno-medical-corp/news/envveno-medical-reports-first-quarter-120500690</link>
<guid isPermaLink="true">https://6ix.com/company/envveno-medical-corp/news/envveno-medical-reports-first-quarter-120500690</guid>
<pubDate>Thu, 01 May 2025 12:05:00 GMT</pubDate>
<description>Cash Burn of $4.0 million in Q1 remains in line with projected quarterly range Cash and investments on hand are sufficient to fund operations beyond the anticipated FDA decision of VenoValve and the initiation of the enVVe pivotal trial FDA decision ...</description>
</item>
</channel>
</rss>